DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

Prothena Corporation (NASDAQ: PRTA)

22.63 -0.12 (-0.53%)

REAL-TIME: Last trade at

Extended Hours: $22.63 $0.00 (0.00%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

PRTA $22.63 -0.53%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $22.50
Previous Close $22.75
Daily Range $22.40 - $23.22
52-Week Range $16.71 - $49.24
Market Cap $619.7M
P/E Ratio 13.15
Dividend (Yield) $0.00 (0.0%)
Volume 249,898
Average Daily Volume 228,064
Current FY EPS -$0.44

Sector

Industry

Prothena Corporation (PRTA) Description

Prothena Corporation plc - Ordinary Shares Website: http://www.prothena.com/

News & Commentary Rss Feed

3 Stocks Poised for Eye-Popping Gains in 2015

Gilead Sciences, Orexigen Therapeutics, and Prothena Corp. are all poised to have a huge 2015. Here's what investors need to know.

Illumina Tops Q4 Earnings on Solid Revenues, Margin Growth - Analyst Blog

Prothena (PRTA) Shares March Higher, Can It Continue? - Tale of the Tape

Prothena (PRTA) Shares March Higher, Can It Continue? - Tale of the Tape

Prothena Corp. (PRTA) Looks Good: Stock Moves Up 5.7% - Tale of the Tape

Health Care Sector Update for 12/16/2014: PRTA,NVGN,CYCC

UPDATE: Prothena Receives FDA Fast Track Designation for NEOD001

Commit To Purchase Prothena Corp At $17.50, Earn 33.1% Annualized Using Options

Prothena Corporation (PRTA) Falls: Stock Goes Down 5% - Tale of the Tape

Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based On Positive Results In Ongoing

Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based On Positive Results In Ongoing Phase 1/2 Study of NEOD001 In Patients With AL Amyloidosis

Prothena Reports Initiation of NEOD001 Global Phase 3 Registrational Trial Based on Positive Results

Prothena Reports Initiation of NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study

See More PRTA News...